Mergers Between Generics: How Competition Commission of India Promotes Innovation and Access Through Merger Control

Research output: Contribution to journalArticleAcademicpeer-review


Indian pharma industry is popularly known as the pharmacy of the world as the industry supplies annually over 10% (in terms of volume) of the worldwide demand for pharma products. This article concentrates on the role of the Competition Commission of India (CCI) in promoting access and innovation in the Indian pharma through its merger control regime. Pursuing an interdisciplinary approach using insights from competition law, economics and corporate strategy, this article attempts to answer the question whether
inorganic growth enhances efficiencies by helping parties leverage their key strengths and seek growth in new relevant product and geographic markets taking into due account the dynamics of the Indian pharma and the core competencies of the merging parties. This article discusses the theory of harm and remedies in all the pharma mergers assessed by the CCI till date.
Original languageEnglish
JournalICC Global Antitrust Review
Publication statusPublished - 2018
Externally publishedYes

Cite this